Developing and Validating a Quick Test for Anxiety and Depression in Childhood Cancer Survivors Ages 7 to 25

What this Trial Is About

Researchers are developing and validating a quick screening tool to identify anxiety and depressive disorders in children, adolescents, and young adults who have survived childhood cancer. This study responds to the need for a fast, practical test that oncologists can use routinely during follow-up visits, as current validated scales take longer and are less feasible for regular use. The study highlights that a significant portion of childhood cancer survivors experience anxiety symptoms in adulthood, emphasizing the importance of psychological monitoring. Participants will complete a new rapid screening test during their regular follow-up consultation. Depending on their age group, they will also complete established questionnaires children aged 7 to 14 will fill out the SCARED-R-51 Screen for Child Anxiety Related Emotional Disorders-Revised, and young adults aged 15 to 25 will complete the HADS Hospital Anxiety and Depression Scale. The study includes three age groups 7-10 years, 11-14 years, and 15-25 years, to validate the tool across these populations. During the study, participants will be assessed at inclusion using both the new screening tool and the age-appropriate reference questionnaires. These assessments aim to measure anxiety and depressive symptoms efficiently. The study is observational and will take place over several years, concluding in September 2027. Participants psychological health will be monitored without altering their usual care, and data from these evaluations will help determine the new tools validity and usefulness in clinical practice.

Validation of a Rapid Screening Tool for Anxiety-depressive Disorders in Children, Adolescents and Young Adults Treated in Oncology. Multicenter Study.